GILEAD SCIENCES, INC. Business Acquisition, Pro Forma Net Income (Loss)
GILEAD SCIENCES, INC. (GILD) reported Business Acquisition, Pro Forma Net Income (Loss) of $4.51 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-02-27
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2012-12-31 was $762.91M, a 20.46% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2012-09-30 was $680.48M, a 0.42% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2012-06-30 was $716.43M, a 4.55% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for the quarter ending 2012-03-31 was $574.38M, a 44.62% increase year-over-year.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for fiscal 2017 was $4.51B, a 65.13% decline from fiscal 2016.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for fiscal 2016 was $12.93B.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for fiscal 2012 was $2.75B, a 14.92% increase from fiscal 2011.
- GILEAD SCIENCES, INC. business acquisition, pro forma net income (loss) for fiscal 2011 was $2.39B.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $4.51B 10-K · filed 2018-02-27 | |||
| 2016-12-31 | $12.93B 10-K · filed 2018-02-27 | |||
| 2012-12-31 | $762.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $1.44B derived: sum of 2 quarters · filed 2013-02-27 | $2.16B derived: sum of 3 quarters · filed 2013-02-27 | $2.75B 10-K · filed 2013-02-27 |
| 2012-09-30 | $680.48M 10-Q · filed 2012-11-06 | $1.40B derived: sum of 2 quarters · filed 2012-11-06 | $1.98B 10-Q · filed 2012-11-06 | $2.60B derived: sum of 4 quarters · filed 2013-02-27 |
| 2012-06-30 | $716.43M 10-Q · filed 2012-08-01 | $1.30B 10-Q · filed 2012-08-01 | $1.92B derived: sum of 3 quarters · filed 2013-02-27 | $2.60B derived: sum of 4 quarters · filed 2013-02-27 |
| 2012-03-31 | $574.38M 10-Q · filed 2012-05-04 | $1.21B derived: sum of 2 quarters · filed 2013-02-27 | $1.89B derived: sum of 3 quarters · filed 2013-02-27 | $2.57B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-12-31 | $633.31M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $1.31B derived: sum of 2 quarters · filed 2013-02-27 | $2.00B derived: sum of 3 quarters · filed 2013-02-27 | $2.39B 10-K · filed 2013-02-27 |
| 2011-09-30 | $677.66M 10-Q · filed 2012-11-06 | $1.36B derived: sum of 2 quarters · filed 2012-11-06 | $1.76B 10-Q · filed 2012-11-06 | |
| 2011-06-30 | $685.26M 10-Q · filed 2012-08-01 | $1.08B 10-Q · filed 2012-08-01 | ||
| 2011-03-31 | $397.17M 10-Q · filed 2012-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |